強気
$4.97
シナリオ価格
$1.730
-0.037 (-2.15%)終値時点
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.
Jones Trading
—
2025-04-02
Jones Trading
2025-04-02
目標株価
—
HC Wainwright & Co.
$26
2025-03-31
HC Wainwright & Co.
2025-03-31
目標株価
$26
HC Wainwright & Co.
$9
2024-11-25
HC Wainwright & Co.
2024-11-25
目標株価
$9
HC Wainwright & Co.
$21
2024-11-06
HC Wainwright & Co.
2024-11-06
目標株価
$21
Jones Trading
$2
2024-09-04
Jones Trading
2024-09-04
目標株価
$2
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

GLIX1 Shows Significant Synergy with PARP Inhibitors

BioLineRx and Hemispherian to Present GLIX1 at SNO Annual Meeting

Lifeward Appoints New CEO and CFO Amid Leadership Transition

BioLineRx Reports Q2 2026 Earnings with Increased R&D Expenses

BioLineRx Reports Significant Progress in GLIX1 Clinical Trials
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment. It operates in the Healthcare sector.
BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.
4 analysts cover BLRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。